CEO Li Yi resigns from Sino
Plus Sekhri becomes CEO of vTv and updates from Eisai, Summit and more
Sino Biopharmaceutical Ltd. (HKEX:1177) hired Eric Tse as CEO, effective July 28. Tse succeeds Li Yi, who was chairman of JP Morgan in China before he joined Sino and is resigning to focus on other business development activities, though will stay on with the company as a senior consultant. Tse, who owns 21.5% of Sino’s issued shares, has served as a director of Chia Tai Tianqing Pharmaceutical Group Co. Ltd. since 2019 and as its president since July 2020. He is the brother of Chairwoman Theresa Tse and son of founding Chairman and Executive Director Ping Tse and Cheng Cheung Ling, who is also an executive director. A Sino Biopharm affiliate, invoX Pharma Ltd., recently acquired oncology company F-star Therapeutics Inc. (NASDAQ:FSTX).
vTv Therapeutics Inc. (NASDAQ:VTVT) named Paul Sekhri as president and CEO, effective Aug. 1. Sekhri was president and CEO at eGenesis Inc., Lycera Corp. and Cerimon Pharmaceuticals Inc., and held business development and strategy roles at Sanofi (Euronext:SAN; NASDAQ:SNY), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), TPG Biotech and Novartis AG (SIX:NOVN; NYSE:NVS). vTv is advancing TTP399, its lead glucokinase activator, into Phase III trials for Type I diabetes. ...